Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
Sandoz (OTCQX:SDZNY), the global leader in generic and biosimilar medicines, has begun construction of a new USD 440 million state-of-the-art biosimilars production center in Brnik, Slovenia. This investment is part of a larger USD 1.1 billion commitment in Slovenia by 2029, which includes a biosimilar drug substance production center in Lendava and a development center in Ljubljana.
The strategic expansion aims to capture a significant portion of the USD 222 billion biosimilar patent-expiry market opportunity expected over the next decade. As the global biosimilar pioneer with 11 marketed molecules and 28 molecules in development, Sandoz is positioning itself to meet growing patient demand through enhanced manufacturing capabilities.
The new Brnik facility will focus on injectable products production, featuring preparation, filling, assembly, and packaging capabilities for sterile injectable products, along with quality control laboratories. The investment aligns with existing capital expenditure commitments and strengthens Sandoz's position as Slovenia's largest direct foreign investor.
[ "Total planned investment of USD 1.1 billion in Slovenia by 2029 demonstrates strong growth commitment", "Company targets USD 222 billion biosimilar patent-expiry market opportunity over next 10 years", "Robust portfolio of 11 marketed molecules and 28 molecules in development pipeline", "Strategic expansion of manufacturing capabilities through new USD 440 million production facility", "Investment strengthens end-to-end European biosimilar hub development" ]Sandoz (OTCQX:SDZNY), leader globale nei medicinali generici e biosimilari, ha avviato la costruzione di un nuovo centro di produzione di biosimilari all'avanguardia del valore di 440 milioni di USD a Brnik, in Slovenia. Questo investimento fa parte di un impegno più ampio di 1,1 miliardi di USD in Slovenia entro il 2029, che comprende un centro di produzione di principi attivi biosimilari a Lendava e un centro di sviluppo a Lubiana.
L'espansione strategica mira a cogliere una parte significativa dell'opportunità di mercato derivante dalla scadenza dei brevetti sui biosimilari, stimata in 222 miliardi di USD nei prossimi dieci anni. Come pioniere globale dei biosimilari con 11 molecole commercializzate e 28 in fase di sviluppo, Sandoz si sta posizionando per soddisfare la crescente domanda dei pazienti attraverso capacità produttive potenziate.
Il nuovo stabilimento di Brnik sarà specializzato nella produzione di prodotti iniettabili, con capacità di preparazione, riempimento, assemblaggio e confezionamento di prodotti sterili iniettabili, oltre a laboratori di controllo qualità. L'investimento è in linea con gli impegni di spesa in conto capitale esistenti e rafforza la posizione di Sandoz come il più grande investitore diretto estero in Slovenia.
Sandoz (OTCQX:SDZNY), líder mundial en medicamentos genéricos y biosimilares, ha iniciado la construcción de un nuevo centro de producción de biosimilares de última generación valorado en 440 millones de USD en Brnik, Eslovenia. Esta inversión forma parte de un compromiso mayor de 1.1 mil millones de USD en Eslovenia para 2029, que incluye un centro de producción de principios activos biosimilares en Lendava y un centro de desarrollo en Liubliana.
La expansión estratégica busca capturar una parte significativa de la oportunidad de mercado por la expiración de patentes de biosimilares, estimada en 222 mil millones de USD durante la próxima década. Como pionero global en biosimilares con 11 moléculas comercializadas y 28 en desarrollo, Sandoz se posiciona para atender la creciente demanda de los pacientes mediante capacidades de manufactura mejoradas.
La nueva instalación en Brnik se centrará en la producción de productos inyectables, con capacidades para preparación, llenado, ensamblaje y empaquetado de productos inyectables estériles, además de laboratorios de control de calidad. La inversión está alineada con los compromisos existentes de gasto de capital y fortalece la posición de Sandoz como el mayor inversor extranjero directo en Eslovenia.
Sandoz (OTCQX:SDZNY)는 제네릭 및 바이오시밀러 의약품 분야의 글로벌 선두주자로서, 슬로베니아 브르니크에 최첨단 바이오시밀러 생산 센터를 4억 4천만 달러 규모로 신축하기 시작했습니다. 이번 투자는 2029년까지 슬로베니아에 총 11억 달러를 투자하는 계획의 일부로, 렌다바에 바이오시밀러 원료 생산 센터와 류블랴나에 개발 센터를 포함합니다.
이번 전략적 확장은 향후 10년간 예상되는 2,220억 달러 규모의 바이오시밀러 특허 만료 시장 기회를 크게 선점하기 위한 것입니다. 11개의 상용화된 분자와 28개의 개발 중인 분자를 보유한 글로벌 바이오시밀러 개척자인 Sandoz는 향상된 제조 역량을 통해 증가하는 환자 수요에 대응할 준비를 하고 있습니다.
브르니크 신규 시설은 주사제 생산에 중점을 두며, 무균 주사제의 준비, 충전, 조립 및 포장 능력과 품질 관리 실험실을 갖출 예정입니다. 이번 투자는 기존의 자본 지출 약속과 일치하며, Sandoz가 슬로베니아에서 가장 큰 직접 외국인 투자자로서의 입지를 강화합니다.
Sandoz (OTCQX:SDZNY), leader mondial des médicaments génériques et biosimilaires, a entamé la construction d'un nouveau centre de production de biosimilaires ultramoderne à Brnik, en Slovénie, pour un montant de 440 millions de dollars US. Cet investissement s'inscrit dans le cadre d'un engagement plus large de 1,1 milliard de dollars US en Slovénie d'ici 2029, qui comprend un centre de production de substances médicamenteuses biosimilaires à Lendava et un centre de développement à Ljubljana.
Cette expansion stratégique vise à capter une part importante de l'opportunité de marché estimée à 222 milliards de dollars US liée à l'expiration des brevets sur les biosimilaires au cours de la prochaine décennie. En tant que pionnier mondial des biosimilaires avec 11 molécules commercialisées et 28 en développement, Sandoz se positionne pour répondre à la demande croissante des patients grâce à des capacités de fabrication renforcées.
La nouvelle installation de Brnik se concentrera sur la production de produits injectables, avec des capacités de préparation, remplissage, assemblage et conditionnement de produits injectables stériles, ainsi que des laboratoires de contrôle qualité. Cet investissement est conforme aux engagements de dépenses en capital existants et renforce la position de Sandoz en tant que principal investisseur direct étranger en Slovénie.
Sandoz (OTCQX:SDZNY), der weltweit führende Anbieter von Generika und Biosimilars, hat mit dem Bau eines neuen hochmodernen Biosimilar-Produktionszentrums in Brnik, Slowenien, begonnen, das 440 Millionen USD kostet. Diese Investition ist Teil eines größeren Engagements von 1,1 Milliarden USD in Slowenien bis 2029, das ein Biosimilar-Wirkstoffproduktionszentrum in Lendava sowie ein Entwicklungszentrum in Ljubljana umfasst.
Die strategische Erweiterung zielt darauf ab, einen bedeutenden Anteil der 222 Milliarden USD großen Marktchance durch das Ablaufen von Biosimilar-Patenten in den nächsten zehn Jahren zu erschließen. Als globaler Pionier im Bereich Biosimilars mit 11 vermarkteten Molekülen und 28 Molekülen in der Entwicklung positioniert sich Sandoz, um die wachsende Patientennachfrage durch verbesserte Produktionskapazitäten zu decken.
Die neue Anlage in Brnik wird sich auf die Herstellung von injizierbaren Produkten konzentrieren und über Kapazitäten für Vorbereitung, Abfüllung, Montage und Verpackung steriler Injektionsprodukte sowie Qualitätskontrolllabore verfügen. Die Investition steht im Einklang mit bestehenden Investitionsverpflichtungen und stärkt die Position von Sandoz als größter direkter ausländischer Investor in Slowenien.
- None.
- None.
MEDIA RELEASE
- Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 years
- Ongoing investment in in-house manufacturing to create end-to-end leading European biosimilar hub, capital expenditure commitments remain unchanged
- Most recent USD 440 million investment in new production plant in Brnik, due to open in 2028, brings total planned investment in Slovenia to more than USD 1.1 billion by 2029
Basel, July 1, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the start of construction for a new, state-of-the-art biosimilars production center for sterile product manufacturing in Brnik, Slovenia. This USD 440 million project brings the company’s total planned and ongoing investment in Slovenia to more than USD 1.1 billion by 2029. It complements ongoing investments in Slovenia, namely a new biosimilar drug substance production center in Lendava and a biosimilar development center in Ljubljana.
The construction start on the new plant marks the latest development in the company’s strategic plan to capture a significant part of an unprecedented market opportunity, with the value of biosimilar patent expiries expected to reach USD 222 billion[1] over the next 10 years. The ongoing investments in in-house capabilities to establish a fully integrated European biosimilar hub are in line with the existing capital expenditure (CapEx) commitments related to Sandoz operations in Slovenia.
Richard Saynor, Chief Executive Officer of Sandoz, said: "Biosimilars is the fastest-growing segment of our pipeline as the need of patients and healthcare systems for these critical medicines continues to grow rapidly. As the global leader in the field, we are investing to meet rapidly growing patient demand. With a commitment of over USD 1.1 billion, we are proud to significantly expand our biosimilar manufacturing capacity in Europe as Slovenia’s largest direct foreign investor. This is another major step that will position Sandoz uniquely to capitalize on the unprecedented biosimilars market opportunity of the next decade."
Glenn Gerecke, Chief Manufacturing and Supply Officer at Sandoz, said: "Our investment in biomanufacturing in the heart of Europe marks another important milestone in building our own independent manufacturing network – one that enhances our control, resilience and agility across the global supply chain. We recognize the strategic value Slovenia brings for us as a company: a highly skilled talent pool in natural sciences and engineering; a central location with world-class logistics infrastructure; cost-competitive production; and a stable, innovation-driven environment closely connected to academia and research."
As the global pioneer and leader in biosimilars, with 11 marketed molecules and an industry-leading pipeline of 28 molecules, Sandoz is uniquely placed to seize this opportunity and play a leading role in ensuring continued patient access to these critical medicines. The new high-tech facility in Brnik will focus on the production of injectable products for both the existing and upcoming portfolio of biosimilars. It will include preparation, filling, assembly and packaging of sterile injectable products, along with laboratories for quality control. Designed with the latest technology, the site will enhance the company’s ability to deliver high-quality, affordable biosimilars to patients worldwide.
Biosimilars are instrumental to ensuring and expanding patient access to biologic medicines and are indispensable for the long-term sustainability of healthcare systems. They contribute to competitiveness, support the supply of essential medicines and fuel innovation while offering more affordable treatment options. The growth of biosimilars is central to the Sandoz strategic roadmap.
Pictures
Please find here the download link to the image material: https://www.lek.si/en/media/multimedia-library/new-bioinjectables-production-center-slovenia/
DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.
REFERENCES
[1] Includes LoE in the period from 2024 to 2035 in major markets (US and EU); LoE dates based on IP databases; originator sales data at LoE-1 from internal analysis and Evaluate Pharma (download Nov 2024)
ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
CONTACTS
| Global Media Relations | Investor Relations |
| Global.MediaRelations@sandoz.com | Investor.Relations@sandoz.com |
| Alex Kalomparis +41 79 279 0285 | Craig Marks +44 7818 942 383 |
| Joerg E. Allgaeuer +49 171 838 4838 | Rupreet Sandhu +41 79 410 5472 |
Attachment
FAQ
What is the total investment Sandoz (SDZNY) is making in Slovenia by 2029?
How much is the biosimilar market opportunity that Sandoz is targeting?
What will the new Sandoz facility in Brnik, Slovenia produce?
How many biosimilar molecules does Sandoz currently have in its portfolio and pipeline?
When will the new Sandoz production plant in Brnik open?
